Andrew Berens
Stock Analyst at Leerink Partners
(1.35)
# 3,374
Out of 4,747 analysts
126
Total ratings
46.94%
Success rate
-10.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $5.19 | +535.84% | 1 | Dec 5, 2024 | |
| ZYME Zymeworks | Upgrades: Outperform | $10 → $25 | $14.45 | +73.01% | 10 | Nov 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $74 → $96 | $95.35 | +0.68% | 1 | Oct 21, 2024 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $33.75 | +65.93% | 11 | Sep 27, 2024 | |
| VIRX Viracta Therapeutics | Downgrades: Market Perform | $5 → $3 | $0.17 | +1,718.18% | 5 | Aug 16, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $11.35 | +155.51% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $113.88 | -14.82% | 24 | May 6, 2024 | |
| NUVL Nuvalent | Upgrades: Outperform | $69 → $110 | $82.59 | +33.19% | 1 | Apr 1, 2024 | |
| INCY Incyte | Upgrades: Outperform | $78 | $72.64 | +7.38% | 12 | Dec 13, 2023 | |
| ELEV Elevation Oncology | Upgrades: Outperform | $5 → $8 | $0.61 | +1,220.57% | 4 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $40.40 | +18.81% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $8.47 | +136.13% | 4 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $19.81 | +41.34% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $74 → $70 | $18.21 | +284.40% | 5 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $70.08 | +12.73% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $2.40 | +1,025.00% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $2.12 | +1,315.09% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $10.30 | +142.72% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $11 | $2.82 | +290.07% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $7.99 | +400.63% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $3.62 | +1,750.83% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $5.75 | +247.83% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.06 | +716.99% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $7.89 | +1.39% | 7 | Jul 14, 2017 |
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $5.19
Upside: +535.84%
Zymeworks
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $14.45
Upside: +73.01%
Gilead Sciences
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $95.35
Upside: +0.68%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $33.75
Upside: +65.93%
Viracta Therapeutics
Aug 16, 2024
Downgrades: Market Perform
Price Target: $5 → $3
Current: $0.17
Upside: +1,718.18%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $11.35
Upside: +155.51%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $113.88
Upside: -14.82%
Nuvalent
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $82.59
Upside: +33.19%
Incyte
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $72.64
Upside: +7.38%
Elevation Oncology
May 30, 2023
Upgrades: Outperform
Price Target: $5 → $8
Current: $0.61
Upside: +1,220.57%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $40.40
Upside: +18.81%
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $8.47
Upside: +136.13%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $19.81
Upside: +41.34%
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $18.21
Upside: +284.40%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $70.08
Upside: +12.73%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $2.40
Upside: +1,025.00%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $2.12
Upside: +1,315.09%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $10.30
Upside: +142.72%
May 5, 2022
Maintains: Outperform
Price Target: $9 → $11
Current: $2.82
Upside: +290.07%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $7.99
Upside: +400.63%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $3.62
Upside: +1,750.83%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $5.75
Upside: +247.83%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $3.06
Upside: +716.99%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $7.89
Upside: +1.39%